Pharming Group N.V. (PHAR)

Market Cap	721.23M
Revenue (ttm)	320.71M
Net Income (ttm)	-14.11M
Shares Out	669.05M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	10.65
Day's Range	n/a
52-Week Range	6.65 - 12.61
Beta	0.54
Analysts	Strong Buy
Price Target	30.00 (+183.55%)
Earnings Date	Jul 31, 2025

About PHAR

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kẟ inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also dev...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1988
• Employees: 404
• Stock Exchange: NASDAQ
• Ticker Symbol: PHAR
• Website: https://www.pharming.com

Financial Performance

In 2024, Pharming Group's revenue was $297.20 million, an increase of 21.15% compared to the previous year's $245.32 million. Losses were -$11.84 million, 12.3% more than in 2023.

Analyst Summary

According to 3 analysts, the average rating for PHAR stock is "Strong Buy." The 12-month stock price target is $30.0, which is an increase of 183.55% from the latest price.

Price Target

$30.0

(183.55% upside)

Analyst Consensus: Strong Buy